Navigation Links
Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
Date:1/6/2011

CARLSBAD, Calif., Jan. 6, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.  

ISIS-FGFR4Rx is designed to treat obesity by increasing metabolism, particularly by increasing lipid and fat burning.  ISIS-FGFR4Rx specifically blocks the production of fibroblast growth factor receptor 4 (FGFR4) in the liver and fat tissue. In addition, ISIS-FGFR4Rx should not reduce FGFR4 expression in the central nervous system (CNS) or heart, thereby avoiding the CNS and cardiovascular side effects associated with many obesity drugs in development.  In preclinical studies, inhibition of FGFR4 lowered body weight and enhanced weight loss when administered as a single agent, in combination with a caloric-restricted diet and in combination with an appetite-suppressing drug and a caloric-restricted diet.  The reduction in body weight was accompanied by an improvement in insulin sensitivity. ISIS-FGFR4Rx was safe and well tolerated in multiple species.  ISIS-FGFR4Rx is the first drug in Isis' metabolic franchise to treat obesity.  

"Obesity has become an epidemic.  It is a condition that increases the risk of diabetes, heart disease, stroke, arthritis and some cancers, and an area where most centrally acting drugs have failed due to side-effects.  Consequently, our peripherally acting drugs such as ISIS-FGFR4Rx could have significant therapeutic benefit without the associated central nervous system toxicities that plague many other anti-obesity drugs.  Our ability to selectively target FGFR4 in only the tissues where FGFR4 plays an important role in modulating body weight, makes it an ideal target for our antisense technology," said Sanjay Bhanot, M.D., Ph.D., Vice President, Metabolic Disorders and Head of Translational Medicine
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
6. Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering
7. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
8. Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
9. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
10. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
11. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that Innovative ... e-Journal and producer of Food Labs Conference , ... the co-location of Food Labs Conference to be held in ... fee to attend the two-day Food Lab Conference, March 4-5. ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... NES-ZIONA, Israel, Sept. 21 PROLOR Biotech, Inc. (OTC ... of a Phase I clinical trial of its long-acting human ... hGH-CTP is being developed to provide growth hormone deficient adults ... per week that are currently required with a once-weekly or ...
... prolonged courses of stable disease and excellent, ... cancer, , , QUEBEC CITY, Sept. ... AEZS ) ("the Company"), a global biopharmaceutical company focused ... a Phase 1 study of its orally-active tubulin and topoisomerase ...
... ... most reliable and secure professional solution to inventory Ultra-low Freezer and Liquid Nitrogen Tank ... ... 21, 2009 -- RURO Inc. today announced the release of FreezerPro 2010, Frozen ...
Cached Biology Technology:PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 2PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 3PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone 4AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer 2AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer 3RURO Inc. Today Announced the Release of FreezerPro 2010, Frozen Sample Inventory and Information Management System 2
(Date:4/22/2014)... 2014) -- There are all sorts of signaling strategies ... their colorful tails; satin bowbirds build specialized stick structures, ... objects; and European bitterling males show off bright nuptial ... unique method to communicate with others. , ... can have profound fitness implications for individuals that are ...
(Date:4/22/2014)... University of Montana,s Wildlife Biology Program, co-wrote a research paper ... Academy of Sciences on how streamwater chemistry varies across ... Lowe and co-authors ... Washington, the Cary Institute of Ecosystem Studies, the University of ... 664 water samples collected every 10 meters along 32 tributaries ...
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3New research focuses on streamwater chemistry, landscape variation 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... at the University of Southampton today, Monday 23 August, ... in Europe, Photon10, the latest developments in ,green photonics, ... technologies undertaken by the United States, Optoelectronics Development Association ... will help reduce CO 2 -creating energy consumption will ...
... Jodie Holt , a professor of plant physiology at ... James Cameron,s film Avatar , will receive ... work as a distinguished scientist and educator" at a ceremony ... Diego Botanic Garden, 230 Quail Gardens Drive, Encinitas, Calif. ...
... NY, August 20, 2010The U.S. needs a comprehensive and ... it remains competitive in the global science and technology ... latest issue of OMICS: A Journal of Integrative ... Liebert, Inc. ( www.liebertpub.com ). The commentary is available ...
Cached Biology News:$240 billion of green photonics by 2021 2A plan to promote sustainable US scientific discovery and innovation in the 21st century is proposed in OMICS 2
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
ANTI ALPHA FSH:B...
... Dog serum is collected from fasted mixed breed, ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
MOUSE ANTI BOVINE TROPONIN I...
Biology Products: